Corgenix Medical Corporation (OTCBB: CONX), a worldwide developer and marketer of diagnostic test kits, today announced a technology transfer and product development agreement with Mellitus LLC of Cambridge, Mass. Mellitus is a private company that is developing a novel in vitro diagnostic test with potential clinical utility for diabetes. The test is based on the measurement of Glycated CD59 (GCD59.)
Under terms of the agreement, Corgenix will develop a test kit to measure GCD59 for Mellitus’ U.S. and European Union commercialization programs. Mellitus’ lead product candidate is a test for Gestational Diabetes Mellitus (GDM). GDM is a major cause of peri- and post-natal complications for mothers and babies.
“We’re pleased to be working with Mellitus on this groundbreaking project,” said Douglass Simpson, Corgenix President and CEO. “This allows us to further demonstrate our capabilities in working with industry partners to establish successful strategic alliances in support of clinical research and product commercialization.”
“Mellitus is dedicated to bringing the GCD59 Test to market. We believe that Corgenix’ in vitro diagnostic development expertise, quality management system and skilled team will make a very important contribution to the development and success of the Mellitus GCD59 in vitro diagnostic test,” said Joyce A. Lonergan, Mellitus CEO and co-founder.
About Mellitus LLC
Mellitus is a private company that was founded to develop and commercialize a novel in vitro diagnostic assay for the measurement of Glycated CD59 (GCD59). GCD59 may provide information about glycemic control, with potential clinical utility in screening, diagnosis and monitoring of diabetes, stratification of complications risk, and as a companion diagnostic for pharmaceutical development. Mellitus’ lead product candidate is an in vitro diagnostic assay for Gestational Diabetes Mellitus (GDM). The GCD59 technology is based on research conducted by Drs. Jose Halperin and Michael Chorev at Harvard Medical School. The technology is part of a patent portfolio exclusively licensed to Mellitus. Mellitus is located in Cambridge, Massachusetts.
About Corgenix Medical Corporation
Corgenix is a leader in the development and manufacturing of specialized diagnostic kits for immunology disorders, vascular diseases (including the world’s only non-blood-based test for aspirin effect), bone and joint disorders and a line of unique detection products for viral hemorrhagic disease. Corgenix diagnostic products are commercialized for use in clinical laboratories throughout the world. The company currently sells over 50 diagnostic products through a global distribution network and has significant experience in product submissions to the FDA and other worldwide regulatory authorities. Additionally, Corgenix contract develops and manufactures products for key medical and life science companies in state-of-the-art facilities in Colorado. The company operates under a Quality Management System that is ISO 13485:2012 certified and compliant with FDA regulations. More information is available at www.corgenix.com (Corporate website) andwww.corgenix.net (Contract Services website).
Statements in this press release that are not strictly historical facts are “forward-looking” statements (identified by the words “believe”, “estimate”, “project”, “expect” or similar expressions) within the meaning of the Private Securities Litigation Reform Act of 1995. These statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, continued acceptance of the Company’s products and services in the marketplace, competitive factors, changes in the regulatory environment, and other risks detailed in the Company’s periodic report filings with the Securities and Exchange Commission. The statements in this press release are made as of today, based upon information currently known to management, and the Company does not undertake any obligation to publicly update or revise any forward-looking statements.